ED
AZN icon

Exane Derivatives’s AstraZeneca AZN Stock Holding History

Exane Derivatives’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25
Closed -$36.5K – 627
2017
Q4 		$36.5K Hold
25
– – 0.01% 362
2017
Q3 		$32.9K Sell
25
-97
-80% -$6.13K 0.01% 334
2017
Q2 		$124K Buy
122
+4
+3% +$261 0.03% 252
2017
Q1 		$63.2K Sell
118
-2,091
-95% -$122K 0.01% 254
2016
Q4 		$67.6K Buy
2,209
+1,847
+510% +$105K 0.01% 271
2016
Q3 		$64.6K Buy
+362
New +$23.7K 0.01% 277
2015
Q4 		– Sell
-855
Closed -$14.5K – 520
2015
Q3 		$14.5K Buy
855
+451
+112% +$29.7K ﹤0.01% 329
2015
Q2 		$14K Sell
404
-896
-69% -$61.3K ﹤0.01% 353
2015
Q1 		$24.2K Buy
1,300
+470
+57% +$32.7K ﹤0.01% 353
2014
Q4 		$22.6K Buy
+830
New +$59.4K ﹤0.01% 380

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Exane Derivatives's AZN Position: Q3 2017 in Review

Exane Derivatives sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 11,577 shares — an estimated $731K sold.

Exane Derivatives first reported a position in AZN in Q4 2014 and held it in 5 quarters. The position peaked at $8.06M in Q3 2016. 454 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

  • Exane Derivatives reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
  • Exane Derivatives sold 11,577 AstraZeneca shares in Q3 2017, an estimated $731K.
  • Exane Derivatives first reported a position in AstraZeneca in Q4 2014 and held it in 5 quarters.
  • Exane Derivatives's AstraZeneca position peaked at $8.06M in Q3 2016.
  • 454 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on Exane Derivatives's 13F filing for Q3 2017, filed 18 Oct 2017.